Innate Pharma to Present Oncology Pipeline at AACR 2026 Industry Partnering Event

Innate Pharma S.A. (Nasdaq: IPHA) announced that its Chief Operating Officer, Yannis Morel, will present at the AACR Oncology Industry Partnering Event on April 16, 2026, in San Diego. The event is a specialized forum for biotechnology and pharmaceutical leaders, venture capitalists, and investment bankers focused on oncology drug development. During the presentation, Innate Pharma will highlight its clinical pipeline and strategies for innovation. Key focus areas include IPH4502, a differentiated Nectin-4 Antibody-Drug Conjugate (ADC) for solid tumors, lacutamab (an anti-KIR3DL2 antibody) for T-cell lymphomas, and monalizumab (an anti-NKG2A antibody) being developed in collaboration with AstraZeneca for non-small cell lung cancer (NSCLC). The company aims to use this platform to showcase the progress of its key assets to analysts and investors and to foster potential collaborations to accelerate the development of its differentiated cancer therapies.